Highest-materiality recent filing
Xenon reports positive Phase 3 X-TOLE2 data for azetukalner; NDA submission planned Q3 2026
Phase 3 X-TOLE2 met primary endpoint: median percent change in monthly FOS -53.2% (25mg) and -34.5% (15mg) vs -10.4% placebo (p<0.0001).
Xenon Pharmaceuticals raises $707.7M in public offering of common shares and pre-funded warrants
Offered 12.2M common shares at $57.00 plus pre-funded warrants for 877,194 shares at $56.9999 each.
Xenon Phase 3 X-TOLE2 azetukalner meets primary endpoint; NDA submission Q3 2026
Primary endpoint MPC: 25mg -53.2% vs placebo -10.4% (p<0.000000000006); placebo-adjusted -42.7%, outperforming Phase 2b.
Xenon reports 2025 net loss of $345.9M; Phase 3 X-TOLE2 data expected in March 2026
Net loss $345.9M in 2025 vs $234.3M in 2024; R&D expense rose to $300.9M on azetukalner Phase 3 trials.
Xenon Q3 net loss $90.9M, Phase 3 FOS study fully enrolled, new CFO appointed
Net loss $90.9M (vs $62.8M Q3 2024) on higher R&D spend; R&D expenses $77.1M (vs $57.0M).
Xenon names Tucker Kelly CFO with $540k salary, 225k options, 30k RSUs
Tucker Kelly appointed CFO effective Oct 15, 2025; replaces interim CFO Ian Mortimer who remains CEO.
Xenon Q2 net loss $84.7M; azetukalner Phase 3 X-TOLE2 enrollment complete, topline early 2026
Net loss $84.7M vs $57.9M Q2 2024; R&D expenses rose to $75.0M from $49.7M on azetukalner trials.
Xenon Q1 net loss $65.0M; X-TOLE2 topline data shifted to early 2026
Net loss of $65.0M (vs $47.9M Q1 2024) on higher R&D spend of $61.2M; revenue $7.5M from Neurocrine milestone.
Xenon reports 2024 net loss $234.3M; CFO resigns; Phase 3 azetukalner FOS data due H2 2025
Net loss for 2024 was $234.3M ($65.7M Q4), vs $182.4M in 2023; R&D spend rose to $210.4M.
Xenon Q3 2024 net loss $62.8M; X-TOLE2 topline data expected H2 2025; COO appointed
Net loss of $62.8M for Q3 2024, compared to $48.5M in Q3 2023; R&D expenses rose to $57.0M.
Xenon Q1 net loss $47.9M; MDD Phase 3 on track for H2 2024 start
Net loss of $47.9M for Q1 2024, up from $41.7M in Q1 2023; cash and securities $885.4M.
Xenon Pharma reports FY2023 net loss $182.4M, cash $930.9M; XEN1101 Phase 3 on track
Net loss of $44.7M in Q4 2023 and $182.4M for FY2023, vs $37.4M and $125.4M in 2022.
Net proceeds ~$281.6M from sale of 8,461,542 common shares and 769,230 pre-funded warrants at $32.50 per share/warrant.
Xenon reports Phase 2 XEN1101 MDD trial misses primary endpoint but hits secondary measures
MADRS at week 6: placebo reduction 13.90; XEN1101 20 mg reduction 16.94 (p=0.135), not statistically significant.
Xenon partner Neurocrine's Phase 2 trial of NBI-921352 in focal seizures fails
Phase 2 study of NBI-921352 in adult focal onset seizures failed to show meaningful seizure reduction.
Xenon Q3 net loss $48.5M; XEN1101 MDD trial topline due late Nov–mid Dec
Net loss $48.5M in Q3 2023 vs $37.2M in Q3 2022; cash $639.1M, funding operations into 2026.
Xenon reports Q2 net loss $47.5M; XEN1101 MDD trial fully enrolled with data expected late Nov-Dec
Q2 net loss $47.5M vs $31.2M YoY; R&D expenses doubled to $44.0M on XEN1101 Phase 3 and MDD trials.
Xenon reports Q1 2023 net loss $41.7M; advances XEN1101 Phase 3 epilepsy trials
Net loss $41.7M ($0.66 per share) vs $19.7M in Q1 2022; no revenue recognized.
Xenon Q3 net loss $37.2M; launches XEN1101 Phase 3 epilepsy program
Revenue $0.1M vs $8.1M YoY; no Neurocrine milestone in Q3 2022.
Xenon Pharma Q2 net loss $31.2M; XEN1101 Phase 3 on track for H2 2022
Net loss of $31.2M for Q2 2022, up from $22.1M in Q2 2021.
Offering of 7,868,854 common shares and pre-funded warrants for 327,868 shares at $30.50/share and $30.4999/warrant.
Xenon announces positive FDA EOP2 meeting for XEN1101; Phase 3 to start H2 2022
FDA aligned on key Phase 3 elements; NDA submission planned after completion of X-TOLE2 trial plus existing Phase 2b data.
Xenon Q1 net loss $19.7M; XEN1101 Phase 3 on track for H2 2022
Net loss $19.7M vs $15.8M YoY; revenue $8.8M, up from $4.4M on Neurocrine milestone.
Xenon reports FY2021 net loss $78.9M; XEN1101 Phase 3 expected H2 2022
Net loss $78.9M vs $28.8M in 2020; revenue $18.4M vs $32.2M.
FDA accepted protocol amendment to expand Phase 2 study of NBI-921352 to children aged 2–11 with SCN8A-DEE.
On February 24, 2025, Ms. Sherry Aulin notified the Company of her decision to resign as Chief Financial Officer, effective June 30, 2025, for personal reasons.
On January 17, 2025, Christopher Von Seggern ceased to be the Chief Commercial Officer of Xenon Pharmaceuticals Inc. (the “Company”) and departed the Company as of such date.
On April 15, 2024, Dr. Simon Pimstone, chair of the board of directors (the “Board”) of Xenon Pharmaceuticals Inc. (the “Company”), and Dr. Mohammad Azab, a member of the Board, each informed the Company of their respective decisions not to stand for re-election to the Board at the Company’s 2024 annual meeting of shareholders (the “AGM”).
On April 15, 2024, Dr. Simon Pimstone, chair of the board of directors (the “Board”) of Xenon Pharmaceuticals Inc. (the “Company”), and Dr. Mohammad Azab, a member of the Board, each informed the Company of their respective decisions not to stand for re-election to the Board at the Company’s 2024 annual meeting of shareholders (the “AGM”).
appointed Dr. Gillian Cannon and Mr. Justin Gover as directors of the Company, effective as of August 8, 2023.
appointed Dr. Gillian Cannon and Mr. Justin Gover as directors of the Company, effective as of August 8, 2023.
appointed Dr. Pimstone, current Executive Chair of the Board, as Chair of the Board, effective upon and subject to his re-election as a director at the Annual Meeting.
Michael Hayden, notified the Board that he would not stand for re-election as a director of the Board at the Annual Meeting.
Max materiality 0.90 · Median 0.57 · Most common event earnings